Search Results - michael+joyce

3 Results Sort By:
Prefusion Coronavirus Spike Proteins and Their Use
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because...
Published: 10/28/2024   |   Inventor(s): Masaru Kanekiyo, Michael Joyce, Kizzmekia Corbett, Hadi Yassine, Jason McLellan, Christopher Cottrell, Nianshuang Wang, Jesper Pallesen, Hannah Turner, Robert Kirchdoerfer, Andrew Ward, Barney Graham
Keywords(s): CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines
Neutralizing Antibodies to Influenza HA and Their Use and Identification
The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe....
Published: 10/28/2024   |   Inventor(s): Robert Bailer, Michael Joyce, John Mascola, Peter Kwong, Sarah Andrews, Paul Thomas, Gwo-Yu Chuang, Adam Wheatley, Yi Zhang, James Whittle, Adrian McDermott
Keywords(s): 1, 2, antibodies, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, GROUP, INFLUENZA, Neutralize, That, Their, Viruses, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies, TherapeuticArea > Immunology
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization...
Published: 10/28/2024   |   Inventor(s): Jason Gorman, Gilad Ofek, Marie Pancera, Mallika Sastry, Sanjay Srivatsan, Yongping Yang, Lei Chen, Cinque Soto, Tongqing Zhou, Barney Graham, Peter Kwong, Masaru Kanekiyo, Michael Joyce, Baoshan Zhang, Guillaume Stewart-Jones, Jeffrey Boyington, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason McLellan
Keywords(s): CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease